Overview

• The Supreme Court ruled 9-0 in favor of the FDA, keeping mifepristone accessible for medication abortions and miscarriage management.
• The decision was based on procedural grounds, concluding that the plaintiffs did not have the standing to sue.
• The FDA had removed several safety protocols for mifepristone in 2016, leading to the legal challenge.
• Medical professionals played a significant role in framing the debate around safety and patient care.
• Reproductive-justice advocates warn that future challenges to mifepristone's availability are likely.